Traduction de «therapy in postmenopausal women » (Français → Néerlandais) :

Arch Intern Med 2006; 166:357-65. Vickers MR, MacLennan AH, Lawton B et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.
Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial.

JAMA 2005; 293:330-9. Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.
JAMA 2005; 293:330-9 Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K. Hormone replacement therapy for cognitive function in postmenopausal women.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women : principal results From the Women’s Health Initiative randomized controlled trial.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial.

Bon à savoir: traitement de substitution hormonale et risque de cancer du sein invasif. Folia Pharmacotherapeutica 2011; 38:4-5. [http ...]
Anderson GL, Limacher M, Assaf AR et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy : the Women’s Health Initiative randomized controlled trial.
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial.

Guidelines for the diagnosis and manegement of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.
Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK.

49. NICE. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.
hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women.

Comme adjuvant d'une thérapie oestrogénique pendant la périménopause et la postménopause, pour la prévention de l'hyperplasie de
Als adjuvans bij een oestrogeentherapie in de peri- en postmenopauze, ter

- Comme adjuvant d'une thérapie oestrogénique pendant la périménopause et la postménopause pour la prévention de l'hyperplasie de l'endomètre.
- Als adjuvans bij een oestrogeentherapie in de peri- en postmenopauze, ter voorkoming van endometriumhyperplasie.

Data on File. ii Siris SE at al Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to
Data on File. ii Siris SE at al Adherence to Bisphosphonate Therapy and Fracture Rates in Osteoporotic Women: Relationship to Vertebral and